Neoplasms, Breast Clinical Trial
Official title:
Implementation of a Prospective Surveillance Rehabilitation Model for Women With Breast Cancer - A Randomized Controlled Trial
Verified date | November 2023 |
Source | University of South Carolina |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Upper extremity strength, range of motion, activity limitations, fatigue and pain are well-documented concerns for women receiving treatment for breast cancer. Research has shown that cancer-related treatment side effects are amenable to rehabilitation interventions when identified early during treatment for breast cancer. Despite this, early rehabilitation has been reported in only 1-2% of individuals diagnosed with cancer. The Prospective Surveillance Model (PSM), a comprehensive model of survivorship care supported by the American Cancer Society and the National Cancer Institute, recommends a baseline assessment (near the time of diagnosis) and ongoing surveillance and intervention of impairments that minimize the impact of cancer treatments. A significant gap in knowledge currently exists with regards to the effectiveness of employing the PSM. The purpose of this study is to examine the impact of implementing the PSM on impairments and functional limitations in women diagnosed with breast cancer during the first six months of treatment. A randomized controlled trial will be applied to examine a total of 28 women diagnosed with stage I-III breast cancer who will receive a mastectomy at Prisma Health in Columbia, S.C. Women will be randomized to one of two groups: PSM or usual care.
Status | Terminated |
Enrollment | 3 |
Est. completion date | March 31, 2023 |
Est. primary completion date | March 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Eligible participants include adult female patients, =18 years of age, with a primary first-time diagnosis of breast cancer, and referred on or after January 1, 2021 for mastectomy surgery. Exclusion Criteria: - Women will be excluded if they will have bilateral surgery, breast-conserving surgery, recurrence of breast cancer, stage IV, or neoadjuvant treatment prior to surgery. |
Country | Name | City | State |
---|---|---|---|
United States | University of South Carolina | Columbia | South Carolina |
Lead Sponsor | Collaborator |
---|---|
University of South Carolina | Prisma Health-Midlands |
United States,
Becker, A.M., Vanlandingham, S., Grogan, M.M., McGowan, M.H., Harrington, S.E. (2019) Impact of Early Rehabilitation in Women Actively Receiving Treatment for Breast Cancer. Rehabilitation Oncology. 38(1): E20, January 2020.
Harrington S, Padua D, Battaglini C, Michener LA, Giuliani C, Myers J, Groff D. Comparison of shoulder flexibility, strength, and function between breast cancer survivors and healthy participants. J Cancer Surviv. 2011 Jun;5(2):167-74. doi: 10.1007/s11764-010-0168-0. Epub 2011 Jan 12. — View Citation
Harrington SE, Stout NL, Hile E, Fisher MI, Eden M, Marchese V, Pfalzer LA. Cancer Rehabilitation Publications (2008-2018) With a Focus on Physical Function: A Scoping Review. Phys Ther. 2020 Mar 10;100(3):363-415. doi: 10.1093/ptj/pzz184. — View Citation
Schmitz KH, Stout NL, Andrews K, Binkley JM, Smith RA. Prospective evaluation of physical rehabilitation needs in breast cancer survivors: a call to action. Cancer. 2012 Apr 15;118(8 Suppl):2187-90. doi: 10.1002/cncr.27471. No abstract available. — View Citation
Stout NL, Andrews K, Binkley JM, Schmitz KH, Smith RA. Stakeholder perspectives on dissemination and implementation of a prospective surveillance model of rehabilitation for breast cancer treatment. Cancer. 2012 Apr 15;118(8 Suppl):2331-4. doi: 10.1002/cncr.27470. — View Citation
Stout NL, Binkley JM, Schmitz KH, Andrews K, Hayes SC, Campbell KL, McNeely ML, Soballe PW, Berger AM, Cheville AL, Fabian C, Gerber LH, Harris SR, Johansson K, Pusic AL, Prosnitz RG, Smith RA. A prospective surveillance model for rehabilitation for women with breast cancer. Cancer. 2012 Apr 15;118(8 Suppl):2191-200. doi: 10.1002/cncr.27476. — View Citation
Stout NL, Silver JK, Raj VS, Rowland J, Gerber L, Cheville A, Ness KK, Radomski M, Nitkin R, Stubblefield MD, Morris GS, Acevedo A, Brandon Z, Braveman B, Cunningham S, Gilchrist L, Jones L, Padgett L, Wolf T, Winters-Stone K, Campbell G, Hendricks J, Perkin K, Chan L. Toward a National Initiative in Cancer Rehabilitation: Recommendations From a Subject Matter Expert Group. Arch Phys Med Rehabil. 2016 Nov;97(11):2006-2015. doi: 10.1016/j.apmr.2016.05.002. Epub 2016 May 27. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Active range of motion | Active range of motion (AROM) will be measured in degrees. Measures will include shoulder flexion, external rotation at 90° of shoulder abduction, and shoulder abduction | Pre-surgery (baseline), 3- and 6-months post-surgery. | |
Secondary | Upper extremity strength | Bilateral peak muscle force in pounds will be assessed for shoulder internal rotation, shoulder external rotation, shoulder scaption, and shoulder horizontal adduction. | Pre-surgery (baseline), 3- and 6-months post-surgery. | |
Secondary | Upper Extremity Function | Patient-Reported Outcomes Measurement Information System (PROMIS) Bank v2.0 - Physical Function will be used to assess Upper Extremity Function. Patient-Reported Outcomes Measurement Information System (PROMIS) Bank v2.0 - Physical Function is a computer adaptive test (CAT) where items related to physical function are dynamically selected for administration from an item bank based on the respondent's previous answers. Usually 4-12 items are answered with a high level of measurement precision. | Pre-surgery (baseline), 3- and 6-months post-surgery. | |
Secondary | Upper Extremity Function | The Disabilities of Arm, Shoulder and Hand (DASH) will be used to assess Upper Extremity Function. The Disabilities of Arm, Shoulder and Hand is a 30-item questionnaire designed to assess patient-reported upper limb function. Scores range from 0-100, with higher scores indicating greater disability. | Pre-surgery (baseline), 3- and 6-months post-surgery. | |
Secondary | Balance | Problems with balance will be determined based on the following question: "In the past 12 months (or since the last visit), have you had a problem with balance or difficulty walking? 1 = Yes, 2 = No". | Pre-surgery (baseline), 3- and 6-months post-surgery. | |
Secondary | Health-Related Quality of Life | The Functional Assessment of Cancer Therapy-Breast version 4 will assess Health-Related Quality of Life. The Functional Assessment of Cancer Therapy-Breast version 4 is a self-report measure and consists of six domains: physical well-being, social/family well-being, emotional well-being, functional well-being, relationship with doctor, and additional concerns that encompass 41 questions. The higher the score, the better the QOL. Total Functional Assessment of Cancer Therapy-Breast+4 total score ranges 0-148, physical well-being subscale scores range 0-28, social/family well-being subscale scores range 0-28, emotional well-being subscale scores range 0-24, functional well-being subscale scores range 0-28, breast cancer subscale subscale scores range 0-40, arm subscale scores range 0-20. | Pre-surgery (baseline), 3- and 6-months post-surgery. 24 hours after baseline assessment, 24 hours after 3-and 6-month post-surgery assessments | |
Secondary | NCCN Distress Thermometer | The NCCN distress thermometer is a brief screening tool that assesses distress in individuals diagnosed with cancer. This is a patient report measure with an 11-point scale from 0 (no distress) to 10 (extreme distress) | Pre-surgery (baseline), 3- and 6-months post-surgery. 24 hours after baseline assessment, 24 hours after 3-and 6-month post-surgery assessments | |
Secondary | NCCN Distress Problem list | The NCCN distress problem list is a brief screening tool that assesses distress in individuals diagnosed with cancer. The problem checklist is answered yes or no and asks whether the indicated level of distress is related to practical, family, emotional, spiritual/religious, or physical problems | Pre-surgery (baseline), 3- and 6-months post-surgery. 24 hours after baseline assessment, 24 hours after 3-and 6-month post-surgery assessments | |
Secondary | Pain interference | Pain will be measured using the Patient-Reported Outcomes Measurement Information System (PROMIS) Bank v1.1 - Pain interference scale. This is a computer adapted test (CAT) where items related to pain interference are dynamically selected for administration from an item bank based on the respondent's previous answers. Usually 4-12 items are answered for each tool with a high level of measurement precision | Pre-surgery (baseline), 3- and 6-months post-surgery. 24 hours after baseline assessment, 24 hours after 3-and 6-month post-surgery assessments | |
Secondary | Pain intensity | Pain intensity will be measured using the Patient-Reported Outcomes Measurement Information System (PROMIS) Scale v1.0 - Pain intensity 3a. This is a computer adapted test (CAT) where items related to pain intensity are dynamically selected for administration from an item bank based on the respondent's previous answers. Usually 4-12 items are answered for each tool with a high level of measurement precision | Pre-surgery (baseline), 3- and 6-months post-surgery. 24 hours after baseline assessment, 24 hours after 3-and 6-month post-surgery assessments | |
Secondary | Fatigue | Fatigue will be assessed using the 10-point numeric rating scale (NRS) for fatigue and the PROMIS Bank v1.0 Fatigue | Pre-surgery (baseline), 3- and 6-months post-surgery. 24 hours after baseline assessment, 24 hours after 3-and 6-month post-surgery assessments | |
Secondary | Falls | Falls in the past 12 months (or since the last visit) will be determined by the following question: "Did you fall in the past 12 months (or since the last visit)? 1 = Yes, 2 = No". | Pre-surgery (baseline), 3- and 6-months post-surgery. | |
Secondary | Arm volume | Arm volume will be assessed by taking circumferential measures using a standard 8mm wide flexible tape measure which will then be used to calculate limb volume using a frustum cone. | Pre-surgery (baseline), 3- and 6-months post-surgery. | |
Secondary | 2-minute step test | To perform the 2-minute step test, the participant will stand next to a wall, without touching, and march in place raising the knees to a marked target on the wall. This target is midway between the lateral epicondyle of the femur, or the lower thigh bone, and the ASIS or the prominent hip bone. The number of times the right knee reaches the marked target over a 2-minute period will be recorded | Pre-surgery (baseline), 3- and 6-months post-surgery. | |
Secondary | 30 second sit to stand | The 30 second sit to stand will be administered using an 18-inch standard office chair without wheels. Starting in a seated position, the patient will fold their arms across their chest without using the armrests or assistance and perform as many sit to stand repetitions as possible in 30 seconds. | Pre-surgery (baseline), 3- and 6-months post-surgery. | |
Secondary | Timed arm curl | , a 5lb weight will be used perform a bicep curl in a seated position. For the starting position, the palm should be facing the participant's body in a resting position. The arm should then rotate so the palm of their hand faces the shoulder at the end of the arm curl. The number of arm curls will be recorded. This will be done on each side. | Pre-surgery (baseline), 3- and 6-months post-surgery. | |
Secondary | Timed up and go | The timed up and go will be administered in a ten-foot walking path marked by a cone. The participant will start in a seated position in a standard office chair without wheels. Time is recorded in seconds while they stand up, walk around the cone and return to a seated position. | Pre-surgery (baseline), 3- and 6-months post-surgery. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00251433 -
GW572016 With Docetaxel and Trastuzumab for the Treatment Of Untreated ErbB2 Over-Expressing Metastatic Breast Cancer
|
Phase 1 | |
Completed |
NCT01271738 -
Evaluating and Comparing Two Surgical Methods for Treatment of Early Stage Breast Cancer
|
N/A | |
Recruiting |
NCT04892342 -
Study of ESG401 in Adults With Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT02213042 -
Evaluation of Biomarkers Associated With Response to Subsequent Therapies in Subjects With HER2-Positive Metastatic Breast Cancer
|
Phase 2 | |
Withdrawn |
NCT01137994 -
A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT00790816 -
Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents
|
Phase 1 | |
Completed |
NCT00051103 -
Oral Drug Study In Women With Refractory Metastatic Breast Cancer After First-line or Second-line Herceptin.
|
Phase 2 | |
Completed |
NCT00320411 -
GW572016 In Patients With ErbB2 Over - Expressing Advanced Or Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT00258050 -
To Examine The Effects Of Lapatinib On Orally And Intravenously Administered Midazolam In Cancer Patients
|
Phase 1 | |
Terminated |
NCT01498588 -
Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer
|
Phase 2 | |
Terminated |
NCT00479856 -
Lapatinib In Combination With Chemotherapy In Subjects With Relapsed Breast Cancer
|
Phase 2 | |
Completed |
NCT00320385 -
Lapatinib In Combination With Trastuzumab Versus Lapatinib Monotherapy In Subjects With HER2-positive Metastatic Breast Cancer
|
Phase 3 | |
Completed |
NCT00062686 -
GW572016 For Treatment Of Refractory Metastatic Breast Cancer
|
Phase 2 | |
Completed |
NCT00996762 -
A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib
|
Phase 1 | |
Terminated |
NCT02913729 -
Pre- Versus Postoperative Accelerated Partial Breast Irradiation
|
N/A | |
Completed |
NCT01160211 -
A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer
|
Phase 3 | |
Recruiting |
NCT05814224 -
Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA
|
N/A | |
Completed |
NCT01815294 -
A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer
|
Phase 1 | |
Terminated |
NCT00437073 -
Brain Metastases In ErbB2-Positive Breast Cancer
|
Phase 2 | |
Completed |
NCT00356811 -
Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer
|
Phase 2 |